Specifying GMP Drug Substance Manufacturing for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Test Article Supply Supporting FDA IND Submission

Nonclinical studies submitted to FDA are only as credible as the test article administered to the animals. This article builds a request for proposal (RFP) for a contract development and manufacturing organization (CDMO) to produce one GMP-compliant batch of drug substance for a hypothetical oral RAS(ON) multi-selective inhibitor candidate, in support of a downstream in vivo genotoxicity study and future IND-enabling work. The RFP specifies a 2.0 kg batch with a stated justification, release specifications aligned with ICH Q3A, Q3C, and Q3D, analytical procedures governed by ICH Q2(R2) and Q14, a stability program under ICH Q1A(R2) for refrigerated storage, a 16-week schedule, an itemized budget of USD 200,000 to 300,000, a weighted scoring model, and a division of responsibilities between the CDMO and the study CRO. The article also clarifies which GMP standard governs drug substance, and closes with recommendations for protecting a sponsor against confidentiality, intellectual property, and copyright exposure in manufacturing engagements.Keywords: request for proposal; GMP; drug substance; CDMO; ICH Q7; ICH Q1A(R2); test article; FDA IND

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425138
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specifying GMP Drug Substance Manufacturing for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Test Article Supply Supporting FDA IND Submission

Avinash Dundigalla, Peivand Pirouzi, Daxaben Jigneshkumar Patel, Afeefa Mahmood et al.
Zenodo (CERN European Organization for Nuclear Research)
Analytical Methods in Pharmaceuticals
article

Specifying GMP Drug Substance Manufacturing for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Test Article Supply Supporting FDA IND Submission

Avinash Dundigalla, Peivand Pirouzi, Daxaben Jigneshkumar Patel, Afeefa Mahmood, Kritica
article en

Abstract

Nonclinical studies submitted to FDA are only as credible as the test article administered to the animals. This article builds a request for proposal (RFP) for a contract development and manufacturing organization (CDMO) to produce one GMP-compliant batch of drug substance for a hypothetical oral RAS(ON) multi-selective inhibitor candidate, in support of a downstream in vivo genotoxicity study and future IND-enabling work. The RFP specifies a 2.0 kg batch with a stated justification, release specifications aligned with ICH Q3A, Q3C, and Q3D, analytical procedures governed by ICH Q2(R2) and Q14, a stability program under ICH Q1A(R2) for refrigerated storage, a 16-week schedule, an itemized budget of USD 200,000 to 300,000, a weighted scoring model, and a division of responsibilities between the CDMO and the study CRO. The article also clarifies which GMP standard governs drug substance, and closes with recommendations for protecting a sponsor against confidentiality, intellectual property, and copyright exposure in manufacturing engagements.Keywords: request for proposal; GMP; drug substance; CDMO; ICH Q7; ICH Q1A(R2); test article; FDA IND

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Specifying GMP Drug Substance Manufacturing for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Test Article Supply Supporting FDA IND Submission — Avinash Dundigalla, Peivand Pirouzi, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS